What pharmacologic treatments are recommended for a 12‑year‑old girl with secondary amenorrhea?

Treatment for Secondary Amenorrhea in a 12-Year-Old Girl

Before initiating any pharmacologic treatment in a 12-year-old with secondary amenorrhea, you must first identify and address the underlying cause—treatment is not amenorrhea itself, but rather the specific etiology (functional hypothalamic amenorrhea, premature ovarian insufficiency, PCOS, hyperprolactinemia, etc.).

Critical First Steps: Diagnosis Before Treatment

Secondary amenorrhea in a 12-year-old requires immediate evaluation to determine the cause, as this will dictate treatment:

Essential Workup

• Pregnancy test (always first, regardless of sexual history)
• FSH, LH, TSH, prolactin levels 1, 2
• If hyperandrogenic signs present (acne, hirsutism): measure androgens 1
• Clinical assessment: eating patterns, exercise habits, weight changes, psychosocial stressors, medication use 2

Treatment Based on Specific Diagnosis

If Functional Hypothalamic Amenorrhea (Most Common in Adolescents)

First-line approach: Address the underlying cause through nutritional rehabilitation, psychological support, and exercise modification—NOT hormonal therapy 3.

If menses do not return after reasonable trial of lifestyle intervention:

• Transdermal 17β-estradiol (50-100 μg patches changed twice weekly) PLUS cyclic oral micronized progesterone (200 mg daily for 12-14 days every 28 days) 3
• Do NOT use combined oral contraceptives or ethinyl estradiol—these suppress IGF-1 and provide minimal bone protection 3
• Transdermal estrogen avoids hepatic first-pass effects and better supports bone mass accrual 3

Critical pitfall: OCPs are commonly prescribed but show limited to no benefit on bone mineral density in functional hypothalamic amenorrhea and do not restore normal endogenous hormonal function 3.

If Premature Ovarian Insufficiency (POI)

First-choice treatment: Transdermal 17β-estradiol (50-100 μg patches or 0.5-1 mg vaginal gel daily) with progestin 4, 5:

When contraception NOT required and withdrawal bleeding acceptable:

• Combined 17β-estradiol + levonorgestrel patches (sequential: 17βE alone for 2 weeks, then combined 17βE + progestin for 2 weeks) 4
• OR transdermal 17β-estradiol continuously + oral micronized progesterone 200 mg (or MPA 10 mg) for 12-14 days every 28 days 4

When contraception IS required:

• First choice: 17β-estradiol-based combined oral contraceptives (17βE + nomegestrol acetate or 17βE + dienogest) 4, 5
• Second choice: ethinyl estradiol-based COCs 4

Rationale: Transdermal route avoids hepatic first-pass effects, reduces cardiovascular and thrombotic risk, and better supports bone mass accrual 4. Micronized progesterone is preferred over synthetic progestins due to lower cardiovascular and thrombotic risk 4.

Continue treatment until age 51 years (average natural menopause age) 5.

If Polycystic Ovary Syndrome (PCOS)

First-line: Lifestyle modification in overweight/obese adolescents 6.

Pharmacologic options:

• Combined hormonal contraceptives for menstrual regulation, hyperandrogenism, and acne—typically most important to adolescents 6
• Metformin may be considered, particularly if insulin resistance present, with promising data in adolescents showing improvements in hyperandrogenemia, ovulation, and dyslipidemia 6
• Must provide contraception counseling if using metformin, as it may increase ovulatory frequency 6

If Hyperprolactinemia

Treatment depends on underlying cause (prolactinoma vs. medication-induced vs. other). Dopamine agonists (cabergoline or bromocriptine) are standard for prolactinomas, but this requires endocrinology referral.

What NOT to Do

• Do NOT use bisphosphonates, denosumab, testosterone, or leptin in adolescents with amenorrhea 3
• Do NOT use progestin-only contraception in POI—it fails to provide estrogen replacement 5
• Do NOT use ethinyl estradiol-based OCPs as first-line in functional hypothalamic amenorrhea or POI—transdermal 17β-estradiol is superior 3, 4
• Do NOT delay evaluation—amenorrhea lasting 3-6 months warrants prompt workup 2, 7

Key Clinical Pearls

• Amenorrhea itself is not a diagnosis—it's a symptom requiring etiologic investigation 1, 2, 8
• At age 12, this patient is only recently post-menarchal, making functional hypothalamic amenorrhea (related to stress, weight loss, excessive exercise) or PCOS most likely 1
• Transdermal estrogen is consistently superior to oral formulations for bone health and metabolic profile in hypogonadal states 4, 3
• Reassure patients and families: hormone replacement therapy at physiological doses in young women with POI does not increase breast cancer risk 5